Quantcast

ASCO: One Step Closer To A Breath Test For Lung Cancer

June 2, 2014

University of Colorado Denver

Volatile organic compounds in exhaled breath show presence and stage of lung cancer

Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present.

“This could totally revolutionize lung cancer screening and diagnosis. The perspective here is the development of a non-traumatic, easy, cheap approach to early detection and differentiation of lung cancer,” says Fred R. Hirsch, MD, PhD, investigator at the CU Cancer Center and professor of medical oncology at the University of Colorado School of Medicine.

The device requires blowing up a balloon, which is then attached to an extremely sensitive gold nanoparticle sensor. The particles in the sensor trap and then help to analyze volatile organic compounds in the exhaled breath. (A USB device has recently been developed, which can be plugged into a computer for rapid analysis).

“The metabolism of lung cancer patients is different than the metabolism of healthy people,” Hirsch says, and it is these differences in metabolism that can define the signatures of healthy breath, COPD or lung cancer.

Hirsch points out the need for new lung cancer screening and diagnosis tools in the context of recent lung cancer screening guidelines by the U.S. Preventative Task Force showing that screening via low-dose computed tomography can reduce disease mortality by 20 percent. However, along with more sensitive screening comes a much higher incidence of false positives, primarily in the form of non-cancerous lung nodules.

“You detect many, many nodules in those screenings and unfortunately, around 90 percent of them are benign. So you need to find out how to better distinguish malignant from benign modules. The goal of this tool is to use breath biomarkers to distinguish malignant from benign screen-detected nodules,” Hirsch says.

The developing device represents a collaboration between the University of Colorado Cancer Center and researchers from the Nobel-Prize-winning institution Technion University in Haifa, Israel.

The device’s potential uses go beyond diagnosis.

“In addition to using levels of volatile organic compounds to diagnose lung cancer, we could eventually measure the change in patients’ levels of VOCs across time with the intent of, for example, monitoring how well a patient responds to specific treatments,” Hirsch says.

A breath now and a breath after treatment could define whether a patient should stay with a drug regimen or explore other options. In fact, a study with this goal was recently initiated at the University of Colorado Cancer Center.

Additionally, Hirsch points out that next generations of the device could potentially help doctors quickly, simply, and inexpensively define patients’ lung cancer subtypes, allowing doctors to pair molecularly targeted therapies with subtypes early in the treatment process.

“If it works, you can imagine standing in the grocery store and having high risk people blow into a balloon or a USB device, and the profile of the organic compounds in their breath would tell you if they are at risk for developing or having lung cancer, which then could lead to further, focused tests,” Hirsch says.


Source: University of Colorado Denver



comments powered by Disqus